A Phase 2 interventional study of HDM1005 dose level 1 and HDM1005 dose level 2 in Obesity, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Obesity by Huadong Medicine Co., Ltd. — 10 open to participants now, 11 under way, 5 of them phase 3. Obesity · Huadong Medicine Co., Ltd..
Among the 13 studies in Obesity by Huadong Medicine Co., Ltd., this one is the 4th largest by planned enrollment, is one of 6 that started in 2026, is one of 3 in phase 2, reaches primary completion later than 8 of the 10 other live ones, and was the 9th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →10 of the 13 studies in Obesity by Huadong Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2024; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 372 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 200 across the 13 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., one of the names counted as Huadong Medicine Co., Ltd.. Under that name alone:
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is the lead sponsor of 50 studies on the registry; 38 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
2 of the studies in Obesity by Huadong Medicine Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07502001Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin | 2026-12-01 |
| NCT07521631Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes | 2027-02-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Obesity by Huadong Medicine Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a 56-week randomized, open-label, controlled study evaluating the efficacy and safety of the HDM1005 compared to tirzepatide in adults with obesity but without diabetes. Eligible participants will be screened and randomized to different dose group of HDM1005 or the tirzepatide group at a ratio of 1:1:1 :1, HDM1005 or tirzepatide will be given once weekly for 52 weeks, following by a safety follow up of 4 weeks. All participants received a lifestyle intervention that involved counselling on diet and physical activity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Hypertension that was not stably controlled at screening: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg (with stable treatment for at least 30 days if antihypertensive medications were used).
Have any malignant tumor within 5 years before signing ICF (except basal cell carcinoma which has received curative treatment and is regarded as cured).
Use of any of the following drugs, products, or treatments within 3 months prior to signing the ICF, including but not limited to:
A. a drug, product or treatment with weight loss effect b. Medications, products, or treatments that significantly increase body weight
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose, the intervention will last for 52 weeks in total.
Drug: HDM1005 dose level 1
Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose, the intervention will last for 52 weeks in total.
Drug: HDM1005 dose level 2
Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose, the intervention will last for 52 weeks in total.
Drug: HDM1005 dose level 3
Initiate at a once weekly dose of 2.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose, the intervention will last for 52 weeks in total.
Drug: Tirzepatide
Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose level 1, the intervention will last for 52 weeks in total.
Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose level 2, the intervention will last for 52 weeks in total.
Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose level 3, the intervention will last for 52 weeks in total.
Initiate at a once weekly dose of 2.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose, the intervention will last for 52 weeks in total.
Primary Outcome
The percentage change in body weight from baseline to week 40
Time frame: week 40
Secondary Outcome
The proportion of participants reaching a body weight loss of at least 5%, 10% and 15% at week 40
Time frame: week 40
Secondary Outcome
The percentage change in body weight from baseline to week 52
Time frame: week 52
Secondary Outcome
Change in waist circumference at week 40
Time frame: week 40
Secondary Outcome
Change in body weight at week 40
Time frame: week 40
Secondary Outcome
Change in BMI at week 40
Time frame: week 40
Secondary Outcome
Change in BMI at week 52
Time frame: week 52
Secondary Outcome
Change in waist circumference at week 52
Time frame: week 52
Secondary Outcome
Change in waist body weight at week 52
Time frame: week 52
Secondary Outcome
Change in systolic blood pressure (SBP) at week 40
Time frame: week 40
Secondary Outcome
Change in diastolic blood pressure (DBP) at week 40
Time frame: week 40
Secondary Outcome
Change in lipids at week 40
Time frame: week 40
Secondary Outcome
Change in SBP at week 52
Time frame: week 52
Secondary Outcome
Change in DBP at week 52
Time frame: week 52
Secondary Outcome
Change in lipids at week 52
Time frame: week 52
Safety Outcome
the incidence of adverse events
Time frame: week 52
Immunogenicity Outcome
ADA and NAb
Time frame: week 52
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Feb 2027, 10 months after the start.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 10 months is below that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HDM1005
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. →